Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged more than 190% over the past 12 months. Analysts expect Solid Biosciences stock to keep going up, predicting that it could more than double in the next 12 months.

The stock has soared as Solid Biosciences advances its gene therapy development programs. On May 7, Solid Biosciences announced that it has begun a Phase 3 trial of its drug candidate SGT-003. The company plans to conduct this trial in multiple countries, including Australia, Canada, US, UK, and the EU zone. The first patient dosed in the Phase 3 study was in Australia.

Solid Biosciences is developing SGT-003 as a treatment for Duchenne muscular dystrophy. SGT-003 has received fast-track, orphan drug, and rare pediatric designations from the FDA.

According to Solid Biosciences, the Phase 3 study is designed to play a major role in supporting various regulatory pathways for gene therapy in the US and internationally. Notably, SGT-003’s Phase 3 study joins the ongoing Phase 1/2 trial of the drug candidate.

Solid Biosciences Inc (NASDAQ:SLDB) is a life sciences company based in Massachusetts. It is focused on developing gene therapies for cardiac and neuromuscular diseases. It targets rare diseases with unmet medical needs.

READ NEXT: 8 Best Middle East and Africa Stocks to Buy According to Hedge Funds and 10 Undervalued Aerospace and Defense Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.